Literature DB >> 18632650

Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

Hiroyoshi Nishikawa1, Takuma Kato, Michiko Hirayama, Yuki Orito, Eiichi Sato, Naozumi Harada, Sacha Gnjatic, Lloyd J Old, Hiroshi Shiku.   

Abstract

We previously found that a Salmonella typhimurium vector engineered to secrete soluble tumor antigen induces CD4(+) T cells resistant to CD4(+)CD25(+) regulatory T cells (Treg) and that glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) signal is involved in the development of this resistance. In this study, we address the potential of incorporating GITR ligand (GITRL) as a way to augment the immunogenicity of cancer vaccines. BALB/c mice were immunized by gene gun with plasmids encoding the mutated extracellular signal-regulated kinase 2 (mERK) with or without plasmids encoding mouse GITRL. Coadministration with GITRL during primary and secondary immunization enhanced the induction of mERK-specific CD8(+) T cells. Antibody depletion and minigene analysis suggested that GITRL directly activated CTL epitope-specific CD8(+) T cells independently of CD4(+) T cells. Immunization with plasmids encoding a CTL epitope and GITRL resulted in strong tumor inhibition in a CD8(+) T cell-dependent manner. Furthermore, CTL epitope-specific CD8(+) T cells induced by immunization with plasmids encoding CTL epitope coadministered with GITRL were refractory to suppression by CD4(+)CD25(+) Tregs compared with CD8(+) T cells induced without GITR signaling. We propose that coadministration of GITR signaling agents with tumor antigens constitutes a promising novel strategy for cancer vaccine development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632650     DOI: 10.1158/0008-5472.CAN-07-5839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Characterization and Comparison of GITR Expression in Solid Tumors.

Authors:  Luis Vence; Samantha L Bucktrout; Irina Fernandez Curbelo; Jorge Blando; Bevin M Smith; Ashley E Mahne; John C Lin; Terrence Park; Edward Pascua; Tao Sai; Javier Chaparro-Riggers; Sumit K Subudhi; Jorge B Scutti; Maria G Higa; Hao Zhao; Shalini S Yadav; Anirban Maitra; Ignacio I Wistuba; James P Allison; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2019-07-29       Impact factor: 12.531

Review 2.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

Review 3.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

4.  Immunological milieu in the peritoneal cavity at laparotomy for gastric cancer.

Authors:  Akira Yoneda; Shinichiro Ito; Seiya Susumu; Mitsutoshi Matsuo; Ken Taniguchi; Yoshitsugu Tajima; Susumu Eguchi; Takashi Kanematsu; Yasuhiro Nagata
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

5.  T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells.

Authors:  Emily R Mercadante; Ulrike M Lorenz
Journal:  J Immunol       Date:  2017-05-26       Impact factor: 5.422

6.  Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.

Authors:  Zuqiang Liu; Xingxing Hao; Yi Zhang; Jiying Zhang; Cara D Carey; Louis D Falo; Walter J Storkus; Zhaoyang You
Journal:  Oncoimmunology       Date:  2017-04-24       Impact factor: 8.110

7.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

8.  Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours.

Authors:  Jinhua Piao; Yosuke Kamimura; Hideyuki Iwai; Yujia Cao; Keisuke Kikuchi; Masaaki Hashiguchi; Taro Masunaga; Hongsi Jiang; Kouichi Tamura; Shimon Sakaguchi; Miyuki Azuma
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

9.  Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells.

Authors:  Il-Kyu Kim; Byung-Seok Kim; Choong-Hyun Koh; Jae-Won Seok; Jun-Seok Park; Kwang-Soo Shin; Eun-Ah Bae; Ga-Eun Lee; Hyewon Jeon; Jaebeom Cho; Yujin Jung; Daehee Han; Byoung S Kwon; Ho-Young Lee; Yeonseok Chung; Chang-Yuil Kang
Journal:  Nat Med       Date:  2015-08-17       Impact factor: 53.440

10.  Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

Authors:  Adam D Cohen; David A Schaer; Cailian Liu; Yanyun Li; Daniel Hirschhorn-Cymmerman; Soo Chong Kim; Adi Diab; Gabrielle Rizzuto; Fei Duan; Miguel A Perales; Taha Merghoub; Alan N Houghton; Jedd D Wolchok
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.